[go: up one dir, main page]

MXPA04000328A - Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer. - Google Patents

Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.

Info

Publication number
MXPA04000328A
MXPA04000328A MXPA04000328A MXPA04000328A MXPA04000328A MX PA04000328 A MXPA04000328 A MX PA04000328A MX PA04000328 A MXPA04000328 A MX PA04000328A MX PA04000328 A MXPA04000328 A MX PA04000328A MX PA04000328 A MXPA04000328 A MX PA04000328A
Authority
MX
Mexico
Prior art keywords
disease
treatment
alzheimer
useful
compounds
Prior art date
Application number
MXPA04000328A
Other languages
English (en)
Inventor
Josef Schostarez Heinrich
Original Assignee
Pharmacia & Upjohn Comapny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Comapny filed Critical Pharmacia & Upjohn Comapny
Publication of MXPA04000328A publication Critical patent/MXPA04000328A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/11—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton
    • C07C255/13—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invencion se refiere a un control mecanico variable de carrera de valvula, mediante el cual pueden ajustarse de manera continua, en valvulas individuales o en grupos de valvulas de motor de combustion interna, la carrera de valvula durante la operacion, de una carrera maxima hasta un estado de cerrado continuo, y al mismo tiempo modificarse el periodo de abertura de las valvulas, siendo que las valvulas se accionan mediante balancines que a su vez son accionados por una palanca angular cuyo cambio de posicion modifica la carrera y el tiempo de abertura de las valvulas. En el control de carrera de valvula se permite un accionamiento de las valvulas en los rangos inferiores de revoluciones por minuto, en el cual para cada carrera de valvula reducida determinada, se obtiene un angulo de giro reducido correspondiente al rango de abertura de las valvulas. Fig. 1 muestra un control de carrera de valvula con una palanca 2 angular accionada lateralmente mediante un rodillo 3 de levas mediante una leva 17, en la cual se efectua durante un ajuste el movimiento de un engranaje planetario de forma tal que el rodillo 9 de la valvula 1 accionando el balancin 8 tiene una funcion como rueda satelite principal, y la palanca 2 angular una funcion como rueda satelite, y la palanca 5 de ajuste una funcion como pinon central.
MXPA04000328A 2001-07-10 2002-07-10 Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer. MXPA04000328A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30412801P 2001-07-10 2001-07-10
US32742401P 2001-10-05 2001-10-05
PCT/US2002/021742 WO2003006021A1 (en) 2001-07-10 2002-07-10 Alpha-hydroxyamide statine derivatives for the treatment of alzh eimer's disease

Publications (1)

Publication Number Publication Date
MXPA04000328A true MXPA04000328A (es) 2004-07-23

Family

ID=26973821

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000328A MXPA04000328A (es) 2001-07-10 2002-07-10 Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.

Country Status (7)

Country Link
US (3) US6864290B2 (es)
EP (1) EP1404328A1 (es)
JP (1) JP2004538274A (es)
BR (1) BR0211122A (es)
CA (1) CA2453447A1 (es)
MX (1) MXPA04000328A (es)
WO (1) WO2003006021A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
JP2006524258A (ja) * 2003-04-21 2006-10-26 イーラン ファーマスーティカルズ、インコーポレイテッド フェナシル２−ヒドロキシ−３−ジアミノアルカン
US20070161700A1 (en) * 2004-12-28 2007-07-12 Kowa Company, Ltd. Inhibitor for the formation of y-secretase complex
JPWO2005063294A1 (ja) * 2003-12-30 2007-12-13 興和株式会社 γ−セクレターゼ複合体形成阻害剤
WO2005087751A2 (en) 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
EP1734942A1 (en) * 2004-03-09 2006-12-27 Elan Pharmaceuticals, Inc. Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
JP2008505930A (ja) 2004-07-09 2008-02-28 エラン ファーマシューティカルズ，インコーポレイテッド オキシム誘導体置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
TW200624426A (en) * 2004-09-21 2006-07-16 Lilly Co Eli BACE inhibitors
US7906625B2 (en) * 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
US20060223849A1 (en) * 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US7838676B2 (en) 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
US7745484B2 (en) * 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) * 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
CA2629402C (en) 2005-11-21 2011-07-26 Amgen Inc. Beta-secretase modulators and methods of use
JP2010518064A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｄおよび関連状態の治療のためのピペラジン誘導体
US20080277393A1 (en) * 2007-05-07 2008-11-13 True Charles W Collapsible, stackable, semi-rigid universal cotainer for hazardous and non-hazardous goods
US8163909B2 (en) 2007-05-25 2012-04-24 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
ES2436364T3 (es) * 2007-05-25 2013-12-30 Amgen Inc. Compuestos de hidroxietilamina sustituidos como moduladores de beta-secretasa y métodos de uso
US20110098309A1 (en) * 2007-07-12 2011-04-28 Acumen Pharmaceuticals, Inc. Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds
US8962677B2 (en) * 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
US9006283B2 (en) 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
WO2009038411A2 (en) * 2007-09-21 2009-03-26 Lg Life Sciences, Ltd. Beta-secretase inhibiting compounds having oxo-dihydro-pyrazole moiety
WO2009038412A2 (en) * 2007-09-21 2009-03-26 Lg Life Sciences, Ltd. Beta-secretase inhibiting compounds
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
CA2707309A1 (en) 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
CA2709354C (en) 2007-12-21 2014-06-17 Amgen Inc. Anti-amyloid antibodies and uses thereof
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
CN102209721A (zh) * 2008-09-11 2011-10-05 安姆根有限公司 作为β-分泌酶调节剂的螺四环化合物及其使用方法
US8822485B2 (en) 2009-11-23 2014-09-02 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2504315A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2526092B1 (en) 2010-01-19 2014-08-06 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2547686B1 (en) 2010-03-15 2014-01-22 Amgen Inc. Amino-dihydrooxazine and amino-dihydrothiazine spiro compounds as beta-secretase modulators and their medical use
MX2012010658A (es) 2010-03-15 2012-12-05 Amgen Inc Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa.
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
US9296759B2 (en) 2011-09-21 2016-03-29 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203836A (es) * 1991-07-02 1993-01-01 Sandoz Ag Derivados de acido-4-amino-3-hidroxicarboxilico y proceso para su preparacion.
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5538997A (en) * 1993-03-12 1996-07-23 Sandoz Ltd. 2,4-diamino-3-hydroxycarboxylic acid derivatives
US5734054A (en) * 1996-11-05 1998-03-31 Pharmacopeia, Inc. Hydroxy-amino acid amides
US5962506A (en) * 1997-07-07 1999-10-05 Pharmacopeia, Inc. Glycol and hydroxyphosphonate peptidomimetics as inhibitors of aspartyl proteases
KR20060111905A (ko) 1998-09-24 2006-10-30 파마시아 앤드 업존 캄파니 엘엘씨 알츠하이머병 세크레타제
AU5619400A (en) 1999-06-15 2001-01-02 Elan Pharmaceuticals, Inc. Statine-derived tetrapeptide inhibitors of beta-secretase

Also Published As

Publication number Publication date
JP2004538274A (ja) 2004-12-24
CA2453447A1 (en) 2003-01-23
US20050159459A1 (en) 2005-07-21
US20030083356A1 (en) 2003-05-01
US7358264B2 (en) 2008-04-15
US7354943B2 (en) 2008-04-08
US20050165069A1 (en) 2005-07-28
US6864290B2 (en) 2005-03-08
WO2003006021A1 (en) 2003-01-23
EP1404328A1 (en) 2004-04-07
BR0211122A (pt) 2004-10-26

Similar Documents

Publication Publication Date Title
MXPA04000328A (es) Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.
TW200512195A (en) Benzamide 2-hydroxy-3-diaminoalkanes
MXPA04002785A (es) Aminas sustituidas para tratamiento de enfermedad de alzheimer.
MXPA04000338A (es) Diamindioles para tratamiento de enfermedad de alzheimer.
WO2004022523A3 (en) 1, 3-diamino-2-hydroxypropane prodrug derivatives
TNSN04017A1 (en) N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
MXPA04003245A (es) Hidroxipropilaminas.
MXPA04006575A (es) Amino carboxamidas sustituidas para el tratamiento de la enfermedad de alzheimer.
TW200505418A (en) Phenacyl 2-hydroxy-3-diaminoalkanes
TW200505828A (en) Substituted ureas and carbamates useful in the treatment of alzheimer's disease
MXPA03011521A (es) Aminadioles para tratamiento de enfermedad de alzheimer.
MXPA03011466A (es) Macrociclos utiles en tratamiento de enfermedades de alzheimer.
UA84407C2 (en) Acetyl 2-hydroxy-1,3 diaminoalkanes
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
AU2002356991A1 (en) Amino acid derivatives useful for the treatment of alzheimer's disease
MXPA03011502A (es) Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.
MXPA04000337A (es) Amindioles para tratamiento de enfermedad de alzheimer.
BR0314180A (pt) Aminoéteres substituìdos para o tratamento da doença de alzheimer
WO2004029019A8 (en) Compounds for the treatment of alzheimer’s disease
WO2002094768A3 (en) Aza hydroxylated ethyl amine compounds
AU2002362008A1 (en) Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease
WO2005042472A3 (en) Hydroxypropyl amides for the treatment of alzheimer’s disease

Legal Events

Date Code Title Description
FG Grant or registration